Hyundai ADM Bio Balance Sheet Health
Financial Health criteria checks 2/6
Hyundai ADM Bio has a total shareholder equity of ₩9.1B and total debt of ₩7.9B, which brings its debt-to-equity ratio to 86.7%. Its total assets and total liabilities are ₩30.1B and ₩21.1B respectively.
Key information
86.7%
Debt to equity ratio
₩7.85b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩9.61b |
| Equity | ₩9.05b |
| Total liabilities | ₩21.07b |
| Total assets | ₩30.12b |
Recent financial health updates
Hyundai ADM Bio (KOSDAQ:187660) Has Debt But No Earnings; Should You Worry?
Dec 19
Is ADM Korea (KOSDAQ:187660) Using Debt Sensibly?
Sep 02Recent updates
Hyundai ADM Bio (KOSDAQ:187660) Has Debt But No Earnings; Should You Worry?
Dec 19Is ADM Korea (KOSDAQ:187660) Using Debt Sensibly?
Sep 02Optimistic Investors Push ADM Korea Inc. (KOSDAQ:187660) Shares Up 36% But Growth Is Lacking
Mar 21Revenues Not Telling The Story For ADM Korea Inc. (KOSDAQ:187660) After Shares Rise 36%
Mar 21Financial Position Analysis
Short Term Liabilities: A187660's short term assets (₩13.7B) do not cover its short term liabilities (₩19.5B).
Long Term Liabilities: A187660's short term assets (₩13.7B) exceed its long term liabilities (₩1.5B).
Debt to Equity History and Analysis
Debt Level: A187660 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if A187660's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A187660 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: A187660 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 78.8% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 14:19 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hyundai ADM Bio Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|